Help

BIO Investor Forum Therapeutic Workshop

Antibody Drug Conjugates: Beyond the ABCs of ADCs

Tuesday, October 25th, 3:30pm-4:25pm, Twin Peaks N/S

The recent FDA approval of Seattle Genetics’ antibody, Adcetris, has cast the spotlight on Antibody Drug Conjugates (ADC), leaving experts to contemplate whether this is the peak for ADCs. If history has its say though, the spotlight won’t be flickering anytime soon. Regulatory hurdles remain an issue, but is the biggest concern CMC or achieving a successful phase 3 program? How do different cancers respond to the ADC approach? Are we limited to chemotoxins in the pipeline today, or are there others on the horizon? Experts in this specialized antibody field will convene to discuss the latest developments and lessons of bringing ADCs through the clinic.

Moderator:

  • Michael King, Managing Director, Rodman & Renshaw, LLC

Panelists:

  • Mark R. Baker, Chief Executive Officer, Progenics Pharmaceuticals, Inc.
  • C. Geoffrey Davis, PhD, Chief Executive Officer, Angelica Therapeutics, Inc.
  • Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine, Seattle Genetics, Inc.
  • Juan Harrison, Vice President, Takeda Ventures
  • Timothy B. Lowinger, PhD, Chief Scientific Officer, Mersana Therapeutics, Inc. 

 


   Who's Who


    

 

Mark R. Baker - Mr. Baker joined Progenics in 2005 as senior vice president and general counsel and secretary, and has since served as executive vice president, president, and was appointed to the board of directors. Mr. Baker began his career in 1979 as a corporate lawyer with the law firm Dewey Ballantine in New York, where he was a partner and co-chairman of the capital markets group, among other positions, until 1997. From 1997 to 2001, he served ContiGroup Companies, Inc. (formerly Continental Grain Company), a privately held international agri-business and financial concern, as executive vice president, chief legal officer and secretary. Mr. Baker was chief business officer, secretary and a director of New York Water Taxi, a privately held passenger ferry operation, from 2003 to 2005. He holds an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law. 

 

C . Geoffrey Davis, PhD - Dr. Davis was a founder and the Chief Scientific Officer for Abgenix, Inc. in Fremont, California, where he led the development of the XenoMouse® technology, was involved in the research and development of Vectabix®, a fully human monoclonal antibody approved for colorectal cancer, and guided the discovery of 11 other antibodies currently in clinical trials.  Abgenix was acquired by Amgen in early 2006.  Prior to founding Abgenix, Dr. Davis was a faculty member at UCSF, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corp. and Cell Genesys, Inc.  Dr. Davis received his Ph.D. in immunology from the University of California, San Francisco and completed his postdoctoral work at the University of Texas Southwestern Medical School at Dallas.  He is the author of 37 publications and is an inventor on 11 issued patents. 

 

Jonathan Drachman, MD - Dr. Drachman joined Seattle Genetics in November 2004. He oversees the company's research, preclinical and early clinical development activities. Prior to joining Seattle Genetics, Dr. Drachman was Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle, where he remains a Clinical Associate Professor of Medicine. He also served as Senior Investigator in the Division of Research and Education and Medical Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center. Dr. Drachman received a B.A. in Biochemistry from Harvard University and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine and fellowship in Medical Oncology at the University of Washington. 

 

Michael G. King, Jr. - Mr. King is a Managing Director and Senior Biotechnology Analyst at Rodman & Renshaw, LLC. He has over 17 years of experience as a leading biotechnology equity research analyst, consistently ranking at the top of Institutional Investor magazine's annual sellР  Р †Р  ‚Р РЋ’side research survey in addition to being named that publication's "Home Run Hitter" in 2000. Most recently, Mr. King served as Senior Vice President of Corporate Development and Communication at ZIOPHARM Oncology (NASDAQ: ZIOP), a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer therapeutics. Prior to joining ZIOPHARM, Mr. King was a Managing Director and Senior Biotechnology Analyst at Wedbush Securities.

Prior to that, Mr. King was a Managing Director and Senior Biotechnology Analyst at Merriman Curhan Ford with other prior positions at leading firms including Dillon Read, Vector Securities International, Robertson Stephens, Banc of America Securities and Rodman & Renshaw, where he was Director of Research. Mr. King began his career in finance in sales at Kidder Peabody.

 

Timothy B. Lowinger -Dr. Lowinger joined Mersana in 2008. He has over eighteen years of experience in the pharmaceutical/biotech industry and brings a wealth of international experience to his role in leading our Research team. From 1993 to 2007, Dr. Lowinger held a number of positions at Bayer Pharmaceuticals in the US, Germany, and Japan, where he contributed to the discovery of more than 15 pre-clinical and clinical candidates in a variety of indications. Most notably, he led the discovery team that invented and advanced Nexavar® (sorafenib), a pioneering anti-angiogenic, anti-cancer agent that is approved for indications including renal and hepatocellular cancer, with Phase 3 studies underway in numerous other cancers. Later, as the VP and Department Head of Chemistry Research in West Haven, he managed a department of over 140 scientists in the disciplines of medicinal, analytical, computational, combinatorial and synthetic chemistry, focused on the discovery and clinical proof-of-concept of new therapeutics for the treatment of cancer, diabetes and obesity. He also served as VP of Chemistry and Pharmaceutical Sciences at Angiotech Pharmaceuticals where he managed a multidisciplinary team of scientists and engineers focused on developing polymer-based pharmaceutical products for local administration as well as medical devices incorporating pharmaceutical agents. Dr. Lowinger has a B.Sc. (Hons.) in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia in Vancouver, Canada, and he was a Merck Postdoctoral Fellow at the Ohio State University in the labs of Professor Leo A. Paquette. Tim has published over 40 scientific papers and is a co-inventor on over 30 patents.